Verition Fund Management’s Indivior Pharmaceuticals INDV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-118,009
Closed -$4.23M – 2902
2025
Q4
$4.23M Buy
+118,009
New +$3.6M 0.02% 1001
2025
Q2
– Sell
-275,088
Closed -$2.62M – 3745
2025
Q1
$2.62M Buy
275,088
+232,022
+539% +$2.44M 0.01% 1384
2024
Q4
$535K Buy
43,066
+4,632
+12% +$47.6K ﹤0.01% 2441
2024
Q3
$375K Buy
+38,434
New +$450K ﹤0.01% 2500

Other funds holding INDV

Verition Fund Management's INDV Position: Q1 2026 in Review

Verition Fund Management sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 118,009 shares — an estimated $4.23M sold.

Verition Fund Management first reported a position in INDV in Q3 2024 and held it in 4 quarters. The position peaked at $4.23M in Q4 2025. 290 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Verition Fund Management reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 118,009 Indivior Pharmaceuticals shares in Q1 2026, an estimated $4.23M.
  • Verition Fund Management first reported a position in Indivior Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Verition Fund Management's Indivior Pharmaceuticals position peaked at $4.23M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.